Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the proceedings of an international galectin meeting, hosted by Galectin Therapeutics and held at the Harvard Club in Boston, MA, on September 17-19, has been accepted for publication by the American Chemical Society. The book, entitled “Galectins and Disease: Implications for Targeted Therapeutics”, is expected to be published in early 2013 and is edited by Dr. Anatole A. Klyosov, Chief Scientist and Founder, and Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, both of Galectin Therapeutics.
“Presentations by international experts in galectin biology and disease confirmed the critical importance of galectin proteins in organ fibrosis and cancer,” said Dr. Traber. “We are pleased that our preclinical data and development programs in liver fibrosis and melanoma were well represented and received by the scientists at the meeting. It was broadly agreed by the participants that this decade will herald the realization of galectin-targeted therapeutics in multiple diseases.”
“In addition to the importance in cancer, the critical role of galectin-3 protein in fibrosis of multiple organs was emphasized, including liver, lung, kidney and heart,” said Dr. Traber. “In fact, one of the speakers indicated that fibrosis of these organs, the ultimate cause of organ failure, accounts for 45% of all mortality in the United States.”
The two and a half day meeting featured 50 participants and 29 presentations by experts from across the United States, Europe and Latin America. The book will include 26 chapters that cover galectin structure and basic biology, galectin mechanisms and therapeutic approaches in cancer, and the mechanisms and therapeutic approaches in inflammation and fibrosis. The focus of the presentations and discussions was how to effectively move the strong basic science in galectins into clinical trials in important human diseases.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV